Hardin Capital Partners’s AbbVie ABBV Stock Holding History

Hardin Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$826K	Sell	3,285 -37	-1%	-$7.96K	0.38%	46
2026 Q1	$723K	Buy	3,322 +1	+0%	+$222	0.34%	48
2025 Q4	$759K	Buy	3,321 +46	+1%	+$10.5K	0.36%	47
2025 Q3	$758K	Buy	3,275 +2	+0.1%	+$407	0.41%	45
2025 Q2	$622K	Buy	3,273 +188	+6%	+$34.9K	0.37%	47
2025 Q1	$646K	Sell	3,085 -3,038	-50%	-$591K	0.4%	43
2024 Q4	$903K	Hold	6,123	–	–	0.54%	30
2024 Q3	$957K	Buy	6,123 +15	+0.2%	+$2.8K	0.54%	27
2024 Q2	$854K	Buy	+6,108	New	+$1.01M	0.56%	27

Other funds holding ABBV

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Hardin Capital Partners's ABBV Position: Q2 2026 in Review

Hardin Capital Partners reduced its AbbVie (ABBV) stake by 1.1% in Q2 2026, selling an estimated $7.96K and leaving 3,285 shares worth $826K. The position accounts for 0.38% of the portfolio, ranked #46.

Hardin Capital Partners first reported a position in ABBV in Q2 2024 and has held it in 9 quarters since. The position peaked at $957K in Q3 2024. 2,655 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Hardin Capital Partners held 3,285 shares of AbbVie worth $826K as of Q2 2026.
Hardin Capital Partners sold 37 AbbVie shares in Q2 2026, an estimated $7.96K.
AbbVie made up 0.38% of Hardin Capital Partners's portfolio in Q2 2026, its #46 holding.
Hardin Capital Partners first reported a position in AbbVie in Q2 2024 and has held it in 9 quarters since.
Hardin Capital Partners's AbbVie position peaked at $957K in Q3 2024.
2,655 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Hardin Capital Partners's 13F filing for Q2 2026, filed 7 Jul 2026.